Photobiomodulation as a novel therapeutic approach in the management of atopic diseases
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Hypersensitivities such as asthma, eczema, and allergic rhinitis, are chronic conditions marked by inflammation and immune system dysfunction. These conditions pose significant health challenges, often leading to an impaired quality of life. Although traditional therapies focus primarily on symptom management, they frequently come with substantial side effects. Photobiomodulation (PBM), a non-invasive treatment involving low-level light therapy, has emerged as a promising alternative. PBM offers a multifaceted approach to addressing the underlying mechanisms of atopic diseases by targeting the key immune pathways, including cytokine production, mast cell stabilization, and T cell modulation. Numerous experimental studies have revealed the therapeutic potential of PBM in various atopic disease models. These findings suggest that PBM may offer a safe and effective adjunct or alternative therapy for individuals suffering from these conditions. Nevertheless, further clinical research is essential to optimize the treatment parameters and fully unlock the therapeutic benefits of PBM. A deeper understanding of PBM’s molecular mechanisms will elucidate its precise mode of action. This can pave the way for the development of targeted therapies that maximize efficacy while minimizing the potential side effects. Ultimately, PBM may revolutionize the management of atopic diseases, offering a more holistic and patient-centered approach to treatment.
Abstract
Hypersensitivities such as asthma, eczema, and allergic rhinitis, are chronic conditions marked by inflammation and immune system dysfunction. These conditions pose significant health challenges, often leading to an impaired quality of life. Although traditional therapies focus primarily on symptom management, they frequently come with substantial side effects. Photobiomodulation (PBM), a non-invasive treatment involving low-level light therapy, has emerged as a promising alternative. PBM offers a multifaceted approach to addressing the underlying mechanisms of atopic diseases by targeting the key immune pathways, including cytokine production, mast cell stabilization, and T cell modulation. Numerous experimental studies have revealed the therapeutic potential of PBM in various atopic disease models. These findings suggest that PBM may offer a safe and effective adjunct or alternative therapy for individuals suffering from these conditions. Nevertheless, further clinical research is essential to optimize the treatment parameters and fully unlock the therapeutic benefits of PBM. A deeper understanding of PBM’s molecular mechanisms will elucidate its precise mode of action. This can pave the way for the development of targeted therapies that maximize efficacy while minimizing the potential side effects. Ultimately, PBM may revolutionize the management of atopic diseases, offering a more holistic and patient-centered approach to treatment.
참고문헌 (47)
- Diaz-Cabrera NM, "Atopy : a collection of comorbid conditions", J Allergy Clin Immunol Pract, 9, pp.3862~3866 (2021)
- Sánchez-Borges M, "The importance of allergic disease in public health : an iCAALL statement", World Allergy Organ J, 11, pp.8~ (2018)
- Dharmage SC, "Epidemiology of asthma in children and adults", Front Pediatr, 7, pp.246~ (2019)
- Kostakou E, "Acute severe asthma in adolescent and adult patients : current perspectives on assessment and management", J Clin Med, 8, pp.1283~ (2019)
- Bawany F, "Sleep disturbances and atopic dermatitis : relationships, methods for assessment, and therapies", J Allergy Clin Immunol Pract, 9, pp.1488~1500 (2021)
- Rahim NA, "Anti-allergic rhinitis effects of medicinal plants and their bioactive metabolites via suppression of the immune system : a mechanistic review", Front Pharmacol, 12, pp.660083~ (2021)
- Bjermer L, "The complex pathophysiology of allergic rhinitis : scientific rationale for the development of an alternative treatment option", Allergy Asthma Clin Immunol, 15, pp.24~ (2019)
- Pavón-Romero GF, "Neuroimmune pathophysiology in asthma", Front Cell Dev Biol, 9, pp.663535~ (2021)
- Figueiredo IAD, "A review of the pathophysiology and the role of ion channels on bronchial asthma", Front Pharmacol, 14, pp.1236550~ (2023)
- Glatthardt T, "The mycobiome in atopic diseases : inducers and triggers", J Allergy Clin Immunol, 152, pp.1368~1375 (2023)
- Abdullah B, "Pharmacological management of allergic rhinitis : a consensus statement from the malaysian society of allergy and immunology", J Asthma Allergy, 15, pp.983~1003 (2022)
- Liu B, "Exploring treatment options in cancer : tumor treatment strategies", Signal Transduct Target Ther, 9, pp.175~ (2024)
- Chang SY, "Photobiomodulation of neurogenesis through the enhancement of stem cell and neural progenitor differentiation in the central and peripheral nervous systems", Int J Mol Sci, 24, pp.15427~ (2023)
- Shamloo S, "The anti-inflammatory effects of photobiomodulation are mediated by cytokines : evidence from a mouse model of inflammation", Front Neurosci, 17, pp.1150156~ (2023)
- Kim JE, "Molecular mechanisms of cutaneous inflammatory disorder : atopic dermatitis", Int J Mol Sci, 17, pp.1234~ (2016)
- Fontanesi F, "Cytochrome c oxidase biogenesis : new levels of regulation", IUBMB Life, 60, pp.557~568 (2008)
- Schieber M, "ROS function in redox signaling and oxidative stress", Curr Biol, 24, pp.R453~R462 (2014)
- Checa J, "Reactive oxygen species : drivers of physiological and pathological processes", J Inflamm Res, 13, pp.1057~1073 (2020)
- Duchen MR, "Mitochondria and calcium : from cell signalling to cell death", J Physiol, 529(Pt 1), pp.57~68 (2000)
- Modesti L, "Mitochondrial Ca2+ signaling in health, disease and therapy", Cells, 10, pp.1317~ (2021)
- Moon TC, "Advances in mast cell biology : new understanding of heterogeneity and function", Mucosal Immunol, 3, pp.111~128 (2010)
- Ryu JH, "Photobiomodulation ameliorates inflammatory parameters in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis", Front Immunol, 14, pp.1122581~ (2023)
- Liu T, "NF-κB signaling in inflammation", Signal Transduct Target Ther, 2, pp.17023~ (2017)
- Kitchen LC, "Rationale for 1068nm photobiomodulation therapy(PBMT)as a novel, non-invasive treatment for COVID-19 and other coronaviruses : roles of NO and Hsp70", Int J Mol Sci, 23, pp.5221~ (2022)
- de Freitas LF, "Proposed mechanisms of photobiomodulation or low-level light therapy", IEEE J Sel Top Quantum Electron, 22, pp.7000417~ (2016)
- Dompe C, "Photobiomodulation-underlying mechanism and clinical applications", J Clin Med, 9, pp.1724~ (2020)
- He Y, "Targeting PI3K", Akt signal transduction for cancer therapy, 2021, pp.6, 425~
- Nejatifard M, "Probable positive effects of the photobiomodulation as an adjunctive treatment in COVID-19 : a systematic review", Cytokine, 137, pp.155312~ (2021)
- de Brito AA, "Photobiomodulation therapy restores IL-10 secretion in a murine model of chronic asthma : relevance to the population of CD4+CD25+Foxp3+ cells in lung", Front Immunol, 12, pp.789426~ (2022)
- Tanaka T, "IL-6 in inflammation, immunity, and disease", Cold Spring Harb Perspect Biol, 6, pp.a016295~ (2014)
- Kany S, "Cytokines in inflammatory disease", Int J Mol Sci, 20, pp.6008~ (2019)
- Iyer SS, "Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease", Crit Rev Immunol, 32, pp.23~63 (2012)
- Carlini V, "The multifaceted nature of IL-10 : regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions", Front Immunol, 14, pp.1161067~ (2023)
- Silva T, "Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis-randomized clinical trial", PLoS One, 15, pp.e0230551~ (2020)
- Stone KD, "IgE, mast cells, basophils, and eosinophils", J Allergy Clin Immunol, 125(2 Suppl 2), pp.S73~S80 (2010)
- Méndez-Enríquez E, "Mast cells and their progenitors in allergic asthma", Front Immunol, 10, pp.821~ (2019)
- Malavazzi TCDS, "Preventive and therapeutic vascular photobiomodulation decreases the inflammatory markers and enhances the muscle repair process in an animal model", J Photochem Photobiol B, 256, pp.112921~ (2024)
- Constant SL, "Induction of Th1 and Th2 CD4+ T cell responses : the alternative approaches", Annu Rev Immunol, 15, pp.297~322 (1997)
- Deo SS, "Role played by Th2 type cytokines in IgE mediated allergy and asthma", Lung India, 27, pp.66~71 (2010)
- Goswami TK, "Regulatory T cells(Tregs)and their therapeutic potential against autoimmune disorders-advances and challenges", Hum Vaccin Immunother, 18, pp.2035117~ (2022)
- Eggenhuizen PJ, "Treg enhancing therapies to treat autoimmune diseases", Int J Mol Sci, 21, pp.7015~ (2020)
- Eisenbarth SC, "Dendritic cell subsets in T cell programming : location dictates function", Nat Rev Immunol, 19, pp.89~103 (2019)
- Gorodilova AV, "The potential of dendritic cell subsets in the development of personalized immunotherapy for cancer treatment", Curr Issues Mol Biol, 45, pp.8053~8070 (2023)
- Park J, "Photobiomodulation mitigates PM2. 5-exacerbated pathologies in a mouse model of allergic asthma", Antioxidants(Basel), 13, pp.1003~ (2024)
- Kim YL, "Effect of low-level laser intervention on dermatitis symptoms and cytokine changes in DNCBinduced atopy mouse model : a randomized controlled trial", Exp Ther Med, 22, pp.1196~ (2021)
- Schapochnik A, "Local(but not systemic)photobiomodulation treatment reduces mast cell degranulation, eicosanoids, and Th2 cytokines in an experimental model of allergic rhinitis", Lasers Med Sci, 37, pp.1953~1962 (2022)
- Sá MGRS, "Effect of photobiomodulation on inflammatory cytokines produced by HaCaT keratinocytes", J Oral Biol Craniofac Res, 14, pp.79~85 (2024)